CLINICAL TRIALS PROFILE FOR APRICITABINE

Clinical Trials for Apricitabine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00126880 ↗	AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV	Completed	Avexa	Phase 2	The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
NCT00334659 ↗	A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects	Completed	Avexa	Phase 1	The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical practice.
NCT00352066 ↗	Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together	Completed	Avexa	Phase 1	The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.

Clinical Trial Conditions for Apricitabine

Condition Name

Condition Name for
Intervention	Trials
HIV Infections	4
HIV Infection	2

Condition MeSH

Condition MeSH for
Intervention	Trials
HIV Infections	6
Infections	3
Infection	1

Clinical Trial Locations for Apricitabine

Trials by Country

Trials by Country for
Location	Trials
United States	18
Australia	4
Canada	3
Peru	1
United Kingdom	1

Trials by US State

Trials by US State for
Location	Trials
Michigan	2
Texas	1
Illinois	1
Kansas	1
Massachusetts	1

Clinical Trial Progress for Apricitabine

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	4
Withdrawn	1
Terminated	1

Clinical Trial Sponsors for Apricitabine

Sponsor Name

Sponsor Name for
Sponsor	Trials
Avexa	6

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	6